Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
APR-1051 by Aprea Therapeutics for Breast Cancer: Likelihood of Approval
APR-1051 is under clinical development by Aprea Therapeutics and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
APR-1051 by Aprea Therapeutics for Ovarian Cancer: Likelihood of Approval
APR-1051 is under clinical development by Aprea Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
APR-1051 by Aprea Therapeutics for Solid Tumor: Likelihood of Approval
APR-1051 is under clinical development by Aprea Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
APR-1051 by Aprea Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
APR-1051 is under clinical development by Aprea Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
APR-1051 by Aprea Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
APR-1051 is under clinical development by Aprea Therapeutics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...